ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
TESTOSTERONE AND OSTEOPOROSIS
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 250958" data-attributes="member: 13851"><p><strong>TESTOSTERONE AND OSTEOPOROSIS (2023)</strong></p><p><em>J.-M. Kaufman </em></p><p>Department of Endocrinology, UZ Gent, Gent, Belgium</p><p></p><p></p><p><em><strong><u>Skeletal effects of testosterone are exerted in part via the androgen receptor and for a substantial part via the estrogen receptors following the aromatization of testosterone to estradiol</u>.</strong> <strong>Androgen receptor-mediated effects of testosterone, and its 5α-reduced active metabolite dihydrotestosterone, can be exerted both directly on the bone cells and indirectly through effects on striated muscles and mechanical loading on the bones.</strong> <strong><u>Sex steroids, both testosterone and estradiol, play an important role in bone maturation and acquisition of peak bone mass during growth as well as in the regulation of bone homeostasis and preservation of skeletal integrity in adult life</u>.</strong> Hypogonadism is a well-recognized secondary cause of osteoporosis in men. Acquired profound hypogonadism such as in men receiving androgen deprivation therapy for prostate cancer, induces high bone turnover, accelerated bone loss, and increased fracture risk. The much more progressive and only modest age-related decline of serum testosterone and its biologically active serum-free fraction has been found to be associated with some skeletal changes. <strong>However, the main effects of sex steroids to help preserve skeletal health in aging men by limiting bone turnover, bone loss, deterioration of trabecular microarchitecture, and cortical porosity <u>appears to be mediated by estradiol acting on the estrogen receptor-α</u>. <u>Low serum estradiol is associated with increased fracture risk with indications for the existence of a critical threshold level</u>.</strong> <strong>Notwithstanding these found associations, in a large US-based prospective study, the measurement of serum testosterone and estradiol did not contribute significantly to the prediction of fracture risk above the predictive power of bone densitometry by DXA and clinical risk factors. <u>Presently, the role of testosterone measurements in the work-up of osteoporosis in men is limited to the exclusion of hypogonadism</u>.</strong> In postmenopausal women aromatization of androgens from the adrenal origin, and in the first years after menopause also originating in part from the ovary, plays an important role as the only source of circulating estrogen. It has indeed been shown that lower postmenopausal estrogen levels adversely affect bone health and high endogenous testosterone levels have also been associated with decreased fracture risk in postmenopausal women. <strong>Potential meaningful clinical implementation of testosterone and estradiol measurements in the context of bone health is presently still hampered by analytical issues and by ill-defined reference ranges for postmenopausal women.</strong></em></p></blockquote><p></p>
[QUOTE="madman, post: 250958, member: 13851"] [B]TESTOSTERONE AND OSTEOPOROSIS (2023)[/B] [I]J.-M. Kaufman [/I] Department of Endocrinology, UZ Gent, Gent, Belgium [I][B][U]Skeletal effects of testosterone are exerted in part via the androgen receptor and for a substantial part via the estrogen receptors following the aromatization of testosterone to estradiol[/U].[/B] [B]Androgen receptor-mediated effects of testosterone, and its 5α-reduced active metabolite dihydrotestosterone, can be exerted both directly on the bone cells and indirectly through effects on striated muscles and mechanical loading on the bones.[/B] [B][U]Sex steroids, both testosterone and estradiol, play an important role in bone maturation and acquisition of peak bone mass during growth as well as in the regulation of bone homeostasis and preservation of skeletal integrity in adult life[/U].[/B] Hypogonadism is a well-recognized secondary cause of osteoporosis in men. Acquired profound hypogonadism such as in men receiving androgen deprivation therapy for prostate cancer, induces high bone turnover, accelerated bone loss, and increased fracture risk. The much more progressive and only modest age-related decline of serum testosterone and its biologically active serum-free fraction has been found to be associated with some skeletal changes. [B]However, the main effects of sex steroids to help preserve skeletal health in aging men by limiting bone turnover, bone loss, deterioration of trabecular microarchitecture, and cortical porosity [U]appears to be mediated by estradiol acting on the estrogen receptor-α[/U]. [U]Low serum estradiol is associated with increased fracture risk with indications for the existence of a critical threshold level[/U].[/B] [B]Notwithstanding these found associations, in a large US-based prospective study, the measurement of serum testosterone and estradiol did not contribute significantly to the prediction of fracture risk above the predictive power of bone densitometry by DXA and clinical risk factors. [U]Presently, the role of testosterone measurements in the work-up of osteoporosis in men is limited to the exclusion of hypogonadism[/U].[/B] In postmenopausal women aromatization of androgens from the adrenal origin, and in the first years after menopause also originating in part from the ovary, plays an important role as the only source of circulating estrogen. It has indeed been shown that lower postmenopausal estrogen levels adversely affect bone health and high endogenous testosterone levels have also been associated with decreased fracture risk in postmenopausal women. [B]Potential meaningful clinical implementation of testosterone and estradiol measurements in the context of bone health is presently still hampered by analytical issues and by ill-defined reference ranges for postmenopausal women.[/B][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
TESTOSTERONE AND OSTEOPOROSIS
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top